Vers une optimisation de la modulation du récepteur des œstrogènes dans le traitement hormonal de la ménopause

The antagonist properties of Bazedoxifene after acute treatment are shifted to stimulatory action after chronic exposure in the liver but not in the uterus

(2018) Mélissa Buscato et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications

(2017) Jean-Francois Arnal et al.   PHYSIOLOGICAL REVIEWS

Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)

(2016) Dan Apter et al.   CONTRACEPTION

Hormone-replacement therapy: current thinking

(2016) Roger A. Lobo   Nature Reviews Endocrinology

Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues

(2016) Zeynep Madak-Erdogan et al.   Science Signaling

Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues

(2016) Zeynep Madak-Erdogan et al.   Science Signaling

Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline

(2015) Cynthia A. Stuenkel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables

(2015) Sven O. Skouby et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Hormones and venous thromboembolism among postmenopausal women

(2014) P.-Y. Scarabin   CLIMACTERIC

The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor   modulation, uncoupling nuclear and membrane activation

(2014) A. Abot et al.   EMBO Molecular Medicine

Genitourinary syndrome of menopause

(2014) David J. Portman et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss

(2014) Barry S. Komm et al.   STEROIDS

Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice

(2014) Jun Ho Kim et al.   Molecular Metabolism

Tamoxifen Elicits Atheroprotection through Estrogen Receptor α AF-1 But Does Not Accelerate Reendothelialization

(2013) Coralie Fontaine et al.   AMERICAN JOURNAL OF PATHOLOGY

Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health

(2013) T. J. de Villiers et al.   CLIMACTERIC

The use of raloxifenein osteoporosis treatment

(2013) Patrizia D'Amelio et al.   EXPERT OPINION ON PHARMACOTHERAPY

Evolution of the tissue selective estrogen complex (TSEC)

(2013) Barry S. Komm et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Tissue-selective estrogen complexes for postmenopausal women

(2013) Sebastian Mirkin et al.   MATURITAS

Mutation of the palmitoylation site of estrogen receptor   in vivo reveals tissue-specific roles for membrane versus nuclear actions

(2013) M. Adlanmerini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial

(2012) L. L. Schierbeck et al.   BMJ-British Medical Journal

Preventive therapy for breast cancer: a consensus statement

(2011) Jack Cuzick et al.   LANCET ONCOLOGY

The Selective Estrogen Receptor Modulator Bazedoxifene Inhibits Hormone-Independent Breast Cancer Cell Growth and Down-Regulates Estrogen Receptor   and Cyclin D1

(2011) J. S. Lewis-Wambi et al.   MOLECULAR PHARMACOLOGY

Roles of transactivating functions 1 and 2 of estrogen receptor-  in bone

(2011) A. E. Borjesson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activation function 2 (AF2) of estrogen receptor-α is required for the atheroprotective action of estradiol but not to accelerate endothelial healing

(2011) Audrey Billon-Galés et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Non-nuclear estrogen receptor α signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice

(2010) Ken L. Chambliss et al.   JOURNAL OF CLINICAL INVESTIGATION

Hormone therapy and recurrence of venous thromboembolism among postmenopausal women

(2010) Valérie Olié et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

(2010) T. J. de Villiers et al.   OSTEOPOROSIS INTERNATIONAL

Mechanisms of Estrogen-Induced Venous Thromboembolism

(2010) Svetlana N. Tchaikovski et al.   THROMBOSIS RESEARCH

Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: Insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens

(2009) Ken C.N. Chang et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Preventive effect of oral estetrol in a menopausal hot flush model

(2008) C. F. Holinka et al.   CLIMACTERIC

Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model

(2008) H. J. T. Coelingh Bennink et al.   CLIMACTERIC

Effects of Various Selective Estrogen Receptor Modulators with or without Conjugated Estrogens on Mouse Mammary Gland

(2008) Bryan J. Peano et al.   ENDOCRINOLOGY

Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial*

(2008) Stuart L Silverman et al.   JOURNAL OF BONE AND MINERAL RESEARCH